File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector

TitleConstruction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector
Authors
Issue Date2009
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2009, v. 27 n. 8, p. 1145-1153 How to Cite?
AbstractIn southern China, as well as in neighboring Asian regions, human adenovirus type 3 (HAdV-3) outbreaks have become very prevalent in recent years. To address this problem regionally and globally, a recombinant virus has been constructed, containing a full-length infectious genomic clone of HAdV-3, to act as a vaccine. This was constructed by using a bacterial homologous recombination mechanism and was based on the cloning, manipulation and maintenance of the full-length adenovirus genome as a stable plasmid in E. coli. The resultant recombinant viral DNA was screened, identified and characterized by duplex PCR, Western blot, indirect immunofluorescence assay and electron microscopy. This putative vaccine strain was shown to be fully infectious in permissive cells, and no genome mutations were found in the recombinant plasmid. To demonstrate the utility of such a vaccine, a recombinant HAdV-3 plasmid expressing the reporter molecule eGFP was also constructed. This confirmed the recombinant protein expression capability. Mice immunized with this recombinant eGFP adenovirus by either intramuscular injection, intragastric or intranasal inoculation routes raised a significant antibody response to eGFP. Our results have provided a solid foundation for development of a recombinant live vaccine and potential more effective adenovirus vector-based delivery system for immune and gene therapy. © 2008 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/157538
ISSN
2015 Impact Factor: 3.413
2015 SCImago Journal Rankings: 2.044
ISI Accession Number ID
Funding AgencyGrant Number
National Natural Science Foundation of China30770102
Funding Information:

This work was supported by The National Natural Science Foundation of China Grant 30770102. We thank Professor Frederick A Murphy of University of Texas Medical Branch for the electron microscopy data.

References

 

DC FieldValueLanguage
dc.contributor.authorZhang, Qen_US
dc.contributor.authorSu, Xen_US
dc.contributor.authorSeto, Den_US
dc.contributor.authorZheng, Ben_US
dc.contributor.authorTian, Xen_US
dc.contributor.authorSheng, Hen_US
dc.contributor.authorLi, Hen_US
dc.contributor.authorWang, Yen_US
dc.contributor.authorZhou, Ren_US
dc.date.accessioned2012-08-08T08:51:04Z-
dc.date.available2012-08-08T08:51:04Z-
dc.date.issued2009en_US
dc.identifier.citationVaccine, 2009, v. 27 n. 8, p. 1145-1153en_US
dc.identifier.issn0264-410Xen_US
dc.identifier.urihttp://hdl.handle.net/10722/157538-
dc.description.abstractIn southern China, as well as in neighboring Asian regions, human adenovirus type 3 (HAdV-3) outbreaks have become very prevalent in recent years. To address this problem regionally and globally, a recombinant virus has been constructed, containing a full-length infectious genomic clone of HAdV-3, to act as a vaccine. This was constructed by using a bacterial homologous recombination mechanism and was based on the cloning, manipulation and maintenance of the full-length adenovirus genome as a stable plasmid in E. coli. The resultant recombinant viral DNA was screened, identified and characterized by duplex PCR, Western blot, indirect immunofluorescence assay and electron microscopy. This putative vaccine strain was shown to be fully infectious in permissive cells, and no genome mutations were found in the recombinant plasmid. To demonstrate the utility of such a vaccine, a recombinant HAdV-3 plasmid expressing the reporter molecule eGFP was also constructed. This confirmed the recombinant protein expression capability. Mice immunized with this recombinant eGFP adenovirus by either intramuscular injection, intragastric or intranasal inoculation routes raised a significant antibody response to eGFP. Our results have provided a solid foundation for development of a recombinant live vaccine and potential more effective adenovirus vector-based delivery system for immune and gene therapy. © 2008 Elsevier Ltd. All rights reserved.en_US
dc.languageengen_US
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_US
dc.relation.ispartofVaccineen_US
dc.rightsVaccine. Copyright © Elsevier Ltd.-
dc.subject.meshAdenoviruses, Human - Genetics - Immunologyen_US
dc.subject.meshAdministration, Intranasalen_US
dc.subject.meshAnimalsen_US
dc.subject.meshAntibodies, Viral - Blooden_US
dc.subject.meshChinaen_US
dc.subject.meshFemaleen_US
dc.subject.meshGenes, Reporteren_US
dc.subject.meshGreen Fluorescent Proteins - Biosynthesis - Genetics - Immunologyen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Intramuscularen_US
dc.subject.meshMiceen_US
dc.subject.meshMice, Inbred Balb Cen_US
dc.subject.meshVaccines, Synthetic - Genetics - Immunologyen_US
dc.subject.meshViral Vaccines - Administration & Dosage - Genetics - Immunologyen_US
dc.titleConstruction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vectoren_US
dc.typeArticleen_US
dc.identifier.emailZhang, Q: zhangqw@HKUCC-COM.hku.hken_US
dc.identifier.emailZheng, B: bzheng@hkucc.hku.hk-
dc.identifier.authorityZheng, Bj=rp00353en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1016/j.vaccine.2008.12.039en_US
dc.identifier.pmid19146906-
dc.identifier.scopuseid_2-s2.0-58749088519en_US
dc.identifier.hkuros156485-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-58749088519&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume27en_US
dc.identifier.issue8en_US
dc.identifier.spage1145en_US
dc.identifier.epage1153en_US
dc.identifier.isiWOS:000263712200002-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridZhang, Q=16177057100en_US
dc.identifier.scopusauthoridSu, X=16319545900en_US
dc.identifier.scopusauthoridSeto, D=8742697000en_US
dc.identifier.scopusauthoridZheng, Bj=7201780588en_US
dc.identifier.scopusauthoridTian, X=25643366500en_US
dc.identifier.scopusauthoridSheng, H=24367122600en_US
dc.identifier.scopusauthoridLi, H=25958185900en_US
dc.identifier.scopusauthoridWang, Y=8836218200en_US
dc.identifier.scopusauthoridZhou, R=7401567052en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats